Guangzhou Xiangxue Pharmaceutical Co., Ltd   Report issue

For profit Phase 1
Founded: Guangzhou China (1997)
Status: No NME R&D (1997)

Organization Overview

First Clinical Trial
2017
NCT03029273
First Marketed Drug
None
First NDA Approval
None
Last Known Activity
2017

Timeline

NOW
  • Now

Indications

Experimental Indications (Clinical Trials, Phases 1-4)


 

Carcinoma (Phase 1)

Carcinoma, Non-Small-Cell Lung (Phase 1)

Esophageal Neoplasms (Phase 1)

Liver Neoplasms (Phase 1)

Neoplasms (Phase 1)

Soft Tissue Neoplasms (Phase 1)

Stomach Neoplasms (Phase 1)

Urinary Bladder Neoplasms (Phase 1)

Overview

  • Highest Phase: Phase 1
  • # of Trials: 2
  • # of Trial APIs: 3